This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

AstraZeneca (AZN) Gets a Buy from Citi

Tipranks - Tipranks - Wed Jul 8, 11:02AM CDT

Citi analyst Graham Parry maintained a Buy rating on AstraZeneca yesterday. The company’s shares closed today at p14,100.00.

4th of July Sale - 70% Off

According to TipRanks, Parry is a 2-star analyst with an average return of 0.8% and a 59.66% success rate.

Currently, the analyst consensus on AstraZeneca is a Strong Buy with an average price target of $214.77, representing a -98.48% downside. In a report released yesterday, Bernstein also maintained a Buy rating on the stock with a p18,900.00 price target.

See the top stocks recommended by analysts >>

Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p15.29 billion and a net profit of p3.08 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p3 billion

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.

Read More on GB:AZN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).